Alpha Teknova, Inc. (TKNO) FY2025 10-K Annual Report
Alpha Teknova, Inc. (TKNO) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 2, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Alpha Teknova, Inc. FY2025 10-K Analysis
Business Overview
- • Core business model: Custom manufacturing of critical reagents for life sciences, supporting research to commercialization stages
- • New emphasis on scaling operations with investment in a new warehouse and distribution facility to improve capacity and efficiency
Risk Factors
- • Regulatory risk: compliance with Second Amended and Restated Credit Agreement net revenue covenant of $39.0M for 2025, minimum cash requirement $8.0M
- • Macroeconomic exposure: 94.4% of revenue from U.S. customers, limited international diversification with only $2.3M (5.6%) sales outside U.S. in 2025
Alpha Teknova, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$41M
▲ +7.4% YoY
Net Income
-$17M
▲ +35.5% YoY
Gross Margin
33.2%
▲ +1401bp YoY
Operating Margin
-41.9%
▲ +2737bp YoY
Net Margin
-42.6%
▲ +2826bp YoY
ROE
-25.1%
▲ +737bp YoY
Total Assets
$104M
▼ -12.8% YoY
EPS (Diluted)
$-0.32
▲ +43.9% YoY
Operating Cash Flow
-$9M
▲ +30.2% YoY
Source: XBRL data from Alpha Teknova, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Alpha Teknova, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.